Kornimate/medical-research-clean huggingface dataset:
three-arm trial of novel treatment for tinea pedis

Conditions: Tinea Pedis

Summary: this is a three-arm randomized controlled trial to assess the efficacy of an experimental treatment in the treatment of tinea pedis (athlete's foot). the experimental treatment will be tested against a vehicle control to determine efficacy and safety, and against an active comparator to evaluate the success of the treatment relative to an existing gold-standard treatment. patients will be treated for four weeks, with their condition being assessed at the end of treatment and two weeks after the end of treatment. the primary endpoint for this study is effective treatment rate at the week 6 evaluation, defined as a mycological cure and minimal clinical signs \& symptoms. secondary endpoints include safety and patient evaluation of treatment.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 or above * clinical diagnosis of tinea pedis * diagnosis confirmed with potassium hydroxide microscopy * availability for the duration of the study (6 weeks) * willingness to comply with study protocol * informed consent exclusion criteria: * moccasin-type tinea pedis * severe maceration of interdigital spaces * severe fissuring * history of dry feet, cracking, fissuring * concurrent onychomycosis * serous exudate or pus * topical antifungal treatment in the past 2 weeks * systemic antifungal treatment in the past 4 weeks * concurrent immunosuppressive or antimicrobial therapy * liver disease * pregnancy or breastfeeding * known hypersensitivity to any ingredients of trial agents

Keywords: tinea pedis athlete's foot
a study to evaluate csj148 in pregnant women with primary hcmv infection

Conditions: HCMV Infection

Summary: the purpose of the study is to evaluate the feasibility of using csj148 to prevent congenital human cytomegalovirus (hcmv) in pregnant women with primary hcmv infection.

this is a randomized, patient, investigator and sponsor blinded, placebo-controlled study in pregnant women with primary hcmv infection. the study has three periods: (i) screening (ii) double-blinded placebo-controlled treatment and (iii) post-delivery follow-up of women and neonates/infants. pregnant women with confirmed primary hcmv infection will participate in periods i and ii. mothers and neonates/infants born to mothers enrolled in the study will participate in period iii.

Eligibility criteria:
inclusion criteria: 1. written informed consent must be obtained before any assessment is performed. 2. pregnant women ≥ 18 years of age with primary hcmv infection occurring between 6 and 24 weeks of gestation 3. ability to receive study drug within 6 weeks of the presumed onset of primary maternal infection. 4. able to communicate well with the investigator, to understand and comply with the requirements of the study. exclusion criteria: 1. confirmed or suspected fetal hcmv infection, defined as positive hcmv dna in amniotic fluid or fetal ultrasound abnormalities suggestive of fetal hcmv disease. 2. prior treatment with any of the following within 30 days prior to enrollment: ganciclovir, valganciclovir, foscarnet, cidofovir, acyclovir (\>25 mg/kg/day iv), valacyclovir (\>3 gm/day oral), famciclovir (\>1500 mg/day oral), hcmv immune globulin, immune globulin (\>500 mg/kg), or any other medication with anti-hcmv activity. 3. any surgical or medical condition (other than pregnancy) which might increase the risk for thrombotic events if the patient is given immune-globulins. these conditions include cryoglobulinemia, monoclonal gammopathies, and hypertriglyceridemia (fasting level \>1000 mg/dl). the investigator should make this determination based on the patient's medical history and laboratory data. 4. history of chronic hepatitis b, hepatitis c and human immunodeficiency virus (hiv) infection. cured hepatitis c in not considered exclusionary. 5. patient request for medical interruption or termination of pregnancy before inclusion. 6. any surgical or medical condition which may jeopardize the patient or fetus in case of participation in the study. the investigator should make this determination in consideration of the patient's obstetrical history. 7. use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations. 8. history of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes. 9. body weight \> 100 kilograms.

Keywords: safety, efficacy pregnant women csj148 hcmv infection congenital hcmv
the effect of a short educational program on young women's knowledge and beliefs about osteoporosis

Conditions: Osteoporosis

Summary: the purpose of the study is to determine the effect of a short educational program on young women's knowledge and beliefs about osteoporosis. they hypothesis is that following the intervention women who receive the educational program will have greater knowledge and beliefs about osteoporosis.

objective. to determine the effect of a short osteoporosis educational program on young women's knowledge and beliefs about osteoporosis. methods. ten college physical activity classes enrolling 133 predominantly caucasian women (age range 18 to 21 years) were randomized to an osteoporosis educational program or control. knowledge and beliefs about osteoporosis were assessed at baseline and at one week and three weeks following the intervention using the multiple osteoporosis prevention survey. knowledge was defined as the ability to identify correctly osteoporosis risk factors. beliefs were measured with the use of a five point likert type scale. the educational program was comprised of a lecture and printed materials developed by the national osteoporosis foundation. chi-square and analysis of variance evaluated for between group differences. alpha was set at 0.05.

Eligibility criteria:
inclusion criteria: * women enrolled in a mid-atlantic college physical activity course exclusion criteria: * unable to partake in three survey's and one educational lesson

Keywords: osteoporosis knowledge beliefs education women
lipoprotein-associated phospholipase a2 in patients with type 2 diabetes

Conditions: Type2 Diabetes

Summary: lipoprotein-associated phospholipase a2 (lp-pla2) is a good marker of cardiovascular risk and inflammation. this study aims at the characteristic and clinical significance of lp-pla2 test in patients with type 2 diabetes(t2d).

the investigators recorded clinical factors, serum levels of glucose, hba1c, lipids and lp-pla2 in patients with t2d who visited in the department of endocrinology at the nanjing first hospital from january 2015 to august 2016. the relationship between levels of lp-pla2 and diabetic complications are analysed.

Eligibility criteria:
inclusion criteria: * patients with t2d and the diagnostic criteria of t2d is according to the world health organization in 1999. exclusion criteria: 1. patients use systemic steroidal anti-inflammatory drugs. 2. patients are pregnant. 3. patients with an acute infection.

Keywords: lipoprotein-associated phospholipase a2
accuracy and outcome of computer-assisted surgery for bony micro-vascular reconstruction in the head and neck region

Conditions: Mandibular Injuries

Summary: background: functional and aesthetic reconstruction of mandibular defects due to tumour invasion, osteoradio- or chemonecrosis or trauma are challenging. surgeons aim to achieve a good anatomic and symmetric reconstruction with stable occlusion and condylar position. classically this was obtained by (pre)bending a reconstruction plate, and providing osteotomies at the vascularized free flap. today there is the availability of cad-cam software enabling a preoperative planning based on 3d models. this computer-assisted surgery (cas) procedure is said to improve accuracy of the postoperative result, as well as a reduce ischemia time. however, there is a need for objective analysis of the accuracy of cas, as well as the effective reduction in operating time and financial implication. study design: retrospective study. all patients undergoing bony reconstruction by free vascularised flap between january 2013 and august 2016 will be included. accuracy will be measured between the planned and actual result, through segmentation of the mandible in brainlab software. parameters regarding ischemic time and financial cost will be obtained from the medical files.


Eligibility criteria:
inclusion criteria: * patients of all ages * patients of both genders * patients requiring mandibular reconstruction due to tumour invasion, osteoradionecrosis, osteochemonecrosis or trauma * all patients undergoing bony reconstruction by free vascularised flap * all patients treated between january 2013 and august 2016 * all patients where cas was applied exclusion criteria: * all patients not eligible according to abovementioned criteria

Keywords: cad-cam software accuracy head and neck region mandibular reconstruction
counterpulsation reduces infarct size pre-pci for ami

Conditions: Acute Myocardial Infarction (AMI)

Summary: subjects with anterior acute stemi who receive an iabc before primary pci will have decreased mi size.

post clearance device study in which subjects with acute mi will be randomized 1:1 to either receive iab or to receive standard of care without iab before mechanical reperfusion. subjects will be followed throughout their hospital stay and at 30 days.

Eligibility criteria:
inclusion criteria: * able to understand and sign an icf * ≥ 18 and ≤ 90 years of age * general good health, in the opinion of the investigator * st elevation of 2mm in 2 contiguous anterior leads or ≥ 4mm total in anterior leads * scheduled for pci \< 6 hours from onset of symptoms of mi exclusion criteria: * known contraindication to mri * prior thrombolytic therapy during the index event * known history of mi * known severe aortic insufficiency * known aortic aneurysm * known severe calcific aorta-iliac disease or peripheral vascular disease * experiencing cardiac shock * known end-stage renal disease * weight \>400 lbs. or height \<4 ft.

Keywords: iabc ami
comparation analgesia efficiency with propofol combine sevoflurane vs propofol

Conditions: Nociceptive Pain; Analgesic Adverse Reaction; Inhalant Use

Summary: this study purpose to compare analgesia efficiency of propofol combine with sevoflurane with propofol only using index of nociception (nox)

1. recently study found sevoflurane plays an important role through spinal nerve peptide receptor (nk.1r), glycine receptor (glyr), neuron nicotinic receptor (nnachrs), methyl-1-methyl-1-day aspartate (nmda receptor), and trpv1 receptor (trpv1 receptor) produce the analgesic efficiency. 2. propofol was traditional sedation reagent. 3. index of nociception (nox) was the objective index for analgesia this study purpose to compare analgesia efficiency of only propofol and sevoflurane combine with propofol using index of nociception (nox)

Eligibility criteria:
inclusion criteria: * participants were aged 18-65 years old, * american society of anesthesiologists (asa) physical status i, ii or iii * scheduled to have urological surgery(would last longer than 1 h) * requiring general anesthesia. exclusion criteria: * refused to participate in this study; * unable to communicate normally because of consciousness alterations; * a history of allergy to opioids * contraindications to inhalational anesthesia * a family history of malignant hyperthermia * a history of alcohol or drug abuse * received central nervous system-active drugs * super obese as defined by a body mass index ≥40 kg/m2 * conditions liable to alter the pharmacokinetic and pharmacodynamic behaviors of the intravenous and inhalation anesthetics * previous head injury * neurologic * psychiatric disease * any disabling central nervous * cerebrovascular disease * using psychoactive * anti-convulsive medications at the time * unstable angina * manifested congestive heart failure * expected difficulty airway management
spatial neglect and bias in near and far space

Conditions: Stroke

Summary: the purpose of this research study is to learn how people distribute their visual attention when looking at objects nearby versus far away, and why vision may become distracted at near versus far distances.

visual distraction is a problem that more often occurs people who have suffered strokes than in the general population. problems of visual attention generally appear immediately following a stroke, and may impair driving and other functions. while it is thought that there is a natural course of improvement over time, little is known about how this improvement occurs. some studies suggest that recovery is only partial, meaning certain aspects of visual attention may improve while other aspects remain but escape notice. the purpose of this study is to examine the effect of stroke on a person's visual attention when looking at objects nearby versus far away, and to learn why a person's visual attention may become more distracted at near versus far distances. the purpose of this study is also to understand how modeled interventions, such as eye patching or prism goggles, affect impairment measures of visual attention. after an initial screening (including attention, thinking, memory, and visual judgment tests), participants will be given a neurological examination. participants may be asked to perform visual tasks while wearing an eye patch or prism goggles. next, they will be asked to perform a line bisection task by looking at lines on a video screen either at close or far distances and, using a laser pointer, marking the center of the lines as they appear on-screen. participants may be asked to perform other, similar visual tasks as well. duration of the study for participants varies, ranging from 1 or 2 sessions totaling approximately 2 hours to multiple sessions spanning a year. research from this study may help researchers better understand problems associated with stroke and may lead to therapies designed to promote improved visual attention.

Eligibility criteria:
inclusion criteria: * the subject has a history of stroke. * the subject is 18 to 100 years old. * the subject is able to give informed consent. * the subject is post-stroke with left-hemisphere injury and has no spatial neglect (no attentional imbalance). * the subject is post-stroke with right hemisphere damage and has spatial neglect (attentional imbalance). * healthy subject with no brain injury. * the subject is post stroke and has hemianopia (a "visual field cut"). * the subject is able and willing to comply with the study protocol, including availability for all scheduled clinic visits. exclusion criteria: * subjects with brain tumors, head injury with loss of consciousness, visual disorders other than corrected near or far-sightedness, history of learning disabilities, dementia or alzheimer's disease.

Keywords: stroke visual spatial neglect
progesterone supplementation in threatened abortion

Conditions: Threatened Abortion; Progesterone Resistance

Summary: to decide whether progesterone supplementation in threatened abortion is a sound practice.

this study was conducted at obstetrics and gynecology department, tanta university in the period from january 2018 to december 2018. patients: eligible patients (n=190) were randomly allocated into 2 groups; study group who will receive progesterone supplementation (prog.group) and control group who will receive no treatment (place.group).

Eligibility criteria:
inclusion criteria: * threatened abortion diagnosed by history and ultrasound examination * singleton * viable fetus * gestational age \< 20 weeks * closed normal length cervix. exclusion criteria: * short cervix \<2 cm multiple pregnancy * dead fetus * open cervix ≥ 2cm * history of cervical surgery * refusal to participate.
the efficacy of sweet orange oil inhalation in management of dental anxiety and pain

Conditions: Aromatherapy

Summary: aim of the study to evaluate the effectiveness of sweet orange oil inhalation in reducing dental anxiety and pain in children undergoing local anaesthetic administration.

research question: can sweet orange oil help to overcome dental anxiety and pain in children undergoing local anaesthetic administration? pico approach: * p: children 8 to 12 years old need dental treatment under local anesthesia. * i: sweet orange oil inhalation. * c: without aromatherapy. * o: primary outcome dental anxiety modified child dental anxiety scale - faces version \[mcdas(f)-simplified\] pulse rate secondary outcome pain wong-baker pain rating scale (wbs)

Eligibility criteria:
inclusion criteria: * • children classified with rating 3 (positive) or 4 (definitely positive) according to frankl behaviour rating scale. * children aged 8-12 years. * patients who need maxillary infiltration anaesthesia in the first dental visit. exclusion criteria: * children with any neurological or psychological disorders. * children with previous la administration. * presence of dental or medical emergency. * presence of systemic disorders. * chidren with common cold. * children with known allergy to topical or local anesthetic agents. * parental refusal for participation.
screening of idh1 and idh2 gene mutations in adult acute myeloid leukemia for possible targeted therapy

Conditions: Acute Myeloid Leukemia

Summary: 1. to assess the incidence of idh1 and idh2 mutations in adult aml patients, and to explore their associations with the patients' clinical, cytogenetic, and molecular characteristics as well as with treatment response and outcome. 2. to delineate the similarities and distinctions among mutations at idh1-r132, idh2-r140 and idh2-r172 in aml, both clinically and molecularly (including cytogenetics, immunophenotyping, mutation co-occurrence patterns). 3. the results can be references for future selection of targeted therapy (targeting idh mutant proteins).

isocitrate dehydrogenases (idh) are enzymes that catalyze oxidative decarboxylation of isocitrate into alpha-ketoglutarate (α-kg). idh1 and idh2 mutations in aml give the enzymes neomorphic enzymatic activity to transform α-kg to d-2hg, an oncometabolite which acts as a competitive inhibitor of dioxygenases, and causes dysregulation of tet2 and histone demethylases, consequently leading to epigenetic reprogramming of a cell, blocking differentiation and contributing to a transformed phenotype, and leukemogenesis. investigators plan to recruit 300 adult aml patients (newly diagnosed or relapsed). 10ml of peripheral blood or marrow blood will be obtained from routine practice blood/marrow sampling specimens (no extra venipuncture or bone marrow aspiration would be required) and sent for routine tests such as cytogenetics, immunophenotyping, and gene mutation analyses. idh1 r132, idh2 r140, and idh2 r172 mutations will be screened by pcr followed by sanger sequencing, as previously described. investigators will first assess the incidence of idh1 and idh2 mutations in adult aml patients, and then explore their associations with the patients' clinical course, cytogenetic, and molecular characteristics as well as with treatment response and outcome. investigators also seek to delineate the similarities and distinctions among idh mutation variants at idh1-r132, idh2-r140 and idh2-r172, both clinically and molecularly (including cytogenetics, immunophenotyping, mutation co-occurrence patterns).

Eligibility criteria:
inclusion criteria: 1. patients ≥20 years with diagnosed acute myeloid leukemia 2. willing to provide voluntary written informed consent before study related procedures exclusion criteria: 1. not acute myeloid leukemia patients 2. patients \<20 years with diagnosed acute myeloid leukemia

Keywords: acute myeloid leukemia idh1 idh2 genetic mutations prognosis
open-label extension of the phase iii study with tramiprosate (3aps) in patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this phase iii open-label extension study is to evaluate the long-term safety of tramiprosate (3aps) in patients with mild to moderate alzheimer's disease.

duration of treatment: 12 months. patients who complete the phase iii clinical trial will be offered the opportunity to receive tramiprosate (3aps) in an open-label extension study

Eligibility criteria:
inclusion criteria: * the patient must have successfully completed the full 78-week duration of the double-blind cl-758007 study. * male or female (age 50 years and older): female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal). * patient must be living in the community with a reliable caregiver. participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver. * the patient must be presenting a reasonably good nutritional status. * signed inform consent from the patient or legal representative. exclusion criteria: patients will not be eligible to participate in the study if they meet any of the following criteria: * the patient participates in another drug trial during the study. * the patient with a clinically significant and/or uncontrolled condition or other significant medical disease. * the patient is unable to swallow medication tablets.
high tone power therapy on neck pain and proprioception in cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: to investigate the effect of high tone power therapy on neck pain and proprioception in cervical radiculopathy patients.

forty two patients with cervical radiculopathy will participate in this study. the patients will randomly be divided into two equal groups; the control group which received the selected exercise program and the study group received the same exercise training program in addition to high tone power therapy, three times per week for four weeks. the evaluation methods are cervical joint position error test, neck disability index, cervical range of motion (crom) and visual analogue scale

Eligibility criteria:
inclusion criteria: * their ages range from 35 to 50 years. * both sex * with mild to moderate cervical disability according to the neck disability index * unilateral cervical radiculopathy for more than 6 months. * cervical radiculopathy due to disc prolapse (c5-c6) (c6-c7) mild to moderate or disc prolapse according to magnetic resonance image (mri). * normal body mass index (18.5 - 24.99kg/m2). exclusion criteria: * any other musculoskeletal disorders of the spine or upper extremity * patients with any other neurological deficits, psychiatric disease cervical myelopathy, cognitive problems, vertebral fractures and previous history of spine or cervical surgery. * neck pain with vertigo or with bilateral upper limbs referred pain. * clinical instability, recent trauma and vertebrobasilar insufficiency. * structural abnormalities of the spine, osteoporosis, and spasmodic torticollis. * inflammatory or other specific disorders of spina such as ankylosing spondylitis and rheumatoid arthritis